Colon News and Research

RSS

A new prognostic marker has shown potential to predict recurrence in certain colon cancer patients

In the study, a team of researchers led by Veridex, LLC, a Johnson & Johnson company, used gene expression profiling to identify the new marker – a 23-gene signature – which may predict disease recurrence in patients initially diagnosed with Dukes' B colon cancer.

29 Apr 2004

Sprouts and broccoli may reduce risk of high blood pressure

Glucoraphanin, also known as sulforaphane glucosinolate (SGS(TM)), a naturally-occurring compound found in broccoli sprouts and broccoli, may reduce risk of high blood pressure, cardiovascular disease and stroke, according to new research published in the May 4 issue of the Proceedings of the National Academy of Sciences of the USA.

28 Apr 2004

AGT Biosciences Limited and ChemGenex Therapeutics today announced merger agreement

AGT Biosciences Limited of Melbourne, Australia and privately held ChemGenex Therapeutics, Inc. of Menlo Park, California, today announced that they have signed a merger agreement. The cross-border merger creates a new, genomics-driven pharmaceutical company with leading edge capabilities for drug discovery and development, as well as two drug candidates in Phase II human trials for cancer.

28 Apr 2004

The cancer death rate for African-American males would drop by nearly two-thirds if their exposure to tobacco smoke was eliminated

The overall cancer death rate for African-American males would drop by nearly two-thirds -- without any other intervention -- if their exposure to tobacco smoke was eliminated, a new study suggests.

25 Apr 2004

New developments in the treatment of pancreatic cancer

A booster dose of a substance already found in the body appears to be safe and non-toxic for the treatment of pancreatic cancer, and shows signs of arresting pancreatic cancer cell growth in patients, Penn State College of Medicine researchers report.

20 Apr 2004

Proteomics helps fight colon cancer

Using new technology associated with the study of proteins, or proteomics, scientists at the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), and their colleagues have made a step toward predicting which people with familial adenomatous polyposis.

19 Apr 2004

Mayo Clinic debunks myths cancer myths

Believing cancer myths can be dangerous to your health, because they could prevent you from having the tests and treatments needed to detect and treat cancer.

16 Apr 2004

Proteomics techniques to find a possible predictor of response in a chemoprevention trial

16 Apr 2004

CT colonography not presently a viable option for colorectal cancer screening

Findings of a new multicenter study by Cotton et al. published today in the Journal of the American Medical Association comparing standard colonoscopy with CT colonography for the detection of colorectal cancer reveal that this technology, in the form used most often in the United States, while of significant interest, is not presently a viable option for routine colorectal cancer screening.

14 Apr 2004

Differing views on virtual colonoscopy accuracy

Demonstrating clearly that not all virtual colonoscopies are equal, the study, published in the December 2003 issue of The New England Journal of Medicine and the American Journal of Roentgenology, found the results found using the Viatronix V3D-Colon system for primary 3D reading to be equal to or better than optical colonoscopy results.

14 Apr 2004

Cancer rates have decreased in men and remained stable in women

Data newly compiled by the American Cancer Society finds death rates for most major cancers continue to decline, but a growing and aging population continues to produce a rise in the total number of cancer deaths.

14 Apr 2004

CT colonography lacks the sensitivity of conventional colonoscopy

A new study published in JAMA on CT colonography or 'virtual' colonoscopy using 2-D imaging finds that this test lacks the sensitivity and specificity of conventional colonoscopy for colorectal cancer screening. Study co-author and American College of Gastroenterology President Douglas K. Rex, M.D. is available for interviews.

13 Apr 2004

Results of Creutzfeldt-Jakob disease research in people who received human growth hormone from cadavers

The largest study of its kind, designed to track the development of Creutzfeldt-Jakob disease in people who received human growth hormone from cadavers, has found that the vast majority of those who received the hormone did not contract the fatal condition. However, some recipients (26 out of approximately 7,700) did develop the disease.

7 Apr 2004

Drug, Nembutal can suppress activity in colon cancer cells

A barbiturate once commonly used to treat anxiety may play a role in controlling the spread of colon cancer, say researchers from The University of Texas M. D. Anderson Cancer Center.

30 Mar 2004

Discovery of gender difference in cartilage cells may help spinal disc repair

When biologist Barbara Boyan discovered science’s first proof of biochemical differences between male and female cartilage cells, she began to question the approaches she and other researchers were taking to study cells. Was their thinking biologically relevant?

30 Mar 2004

Discovery of novel gene profile that may identify colon stem cells

Researchers at Jefferson Medical College have uncovered a novel pattern of gene expression in the stem cell-rich bottom of tiny “crypts” in the tissue lining the colon. By identifying these patterns, the scientists hope to be able to identify mechanisms through which stem cells contribute to the development of colon cancer.

30 Mar 2004

Researchers find new purpose for existing drugs to suppress colon cancer metastasis, secure post-radiation brain function, and trick tumors

Drugs approved for treatment of specific maladies sometimes show unexpected benefits. Researchers at the 95th annual meeting of the American Association for Cancer Research demonstrated highlighted how some drugs may one day offer previously unforeseen benefits for patients.

30 Mar 2004

New research to predict patient response to cancer chemotherapies

Timothy J. Yeatman, M.D., Moffitt's Associate Center Director for Clinical Investigations at the H. Lee Moffitt Cancer Center & Research Institute, and the Sarasota-based DNAPrintTM genomics, Inc., have formed a joint research program to develop and implement new clinical tests for predicting patient response to cancer chemotherapies.

29 Mar 2004

Enzyme called COX-2 may promote the development of ovarian tumors

Fox Chase Cancer Center scientists have identified how an enzyme called COX-2 may promote the development of ovarian tumors, adding further insight into the mechanism of COX-2 inhibitors and the prevention of this highly lethal disease. The data was presented today at the 95th Annual Meeting of the American Association for Cancer Research in Orlando, Fla.

29 Mar 2004

Novel vaccine technology to suppress the growth of certain tumors

MedImmune, Inc. and Cerus Corporation have announced preclinical results demonstrating the effectiveness of a novel therapeutic vaccine technology in suppressing the growth of certain tumors.

From Baxter International Inc. 29 Mar 2004